GSK to pay $317K in EPA settlement; Cipla profits fall short; Amnal adding Northern Ireland jobs;

@FiercePharma: ICYMI: This week's issue of FiercePharmaMarketing. Want more? Subscribe here. | Follow @FiercePharma

@EricPFierce: ICYMI yesterday: Merck KGaA has to rely on AZ as its pharma sales contract in Q2. Article | Follow @EricPFierce

@CarlyHFierce: Sovaldi payer pushback hurting access for opioid treatment patients. Story | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) agreed to pay $317,550 and to manage its hazardous waste properly in a deal with the U.S. Environmental Protection agency over alleged violations at an R&D facility in Pennsylvania. Report

> India's Cipla posted lower-than-expected profits of 2.95 billion rupees ($48.6 million) because higher costs ate away at the bottom line. Report

> The pharma company Amnal Group plans to add 350 jobs in two divisions at its Northern Ireland headquarters. Report

> Hong Kong's customs department is scrutinizing the safety of Colgate's Total toothpaste, which contains the controversial chemical triclosan. Report

Medical Device News

@FierceMedDev: ICYMI: Here's yesterday's issue of FierceDrugDelivery. | Follow @FierceMedDev

@StacyALawrence: You're so fierce: A call for nominations of the top women in med tech. Editor's corner | Follow @StacyALawrence

@VarunSaxena2: Big VC scoop from my colleague : Sofinnova spinoff HealthQuest targets $110M, makes first investments. News | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: Medicated electrospun fabric offers alternative delivery method for HIV-preventing drugs. FierceDrugDelivery story | Follow @EmilyWFierce

> J&J freed from Stryker lawsuit, could face renewed battle with Medinol over stent patents. More

> Sofinnova spinoff HealthQuest targets $110M, makes first investments. Story

> California devicemaker rakes in $15M for innovative transcarotid stent system. Article

Biotech News

@FierceBiotech: Merck wins FDA nod for a weaker form of its embattled sleep drug. Article | Follow @FierceBiotech

@DamianFierce: ICYMI yesterday: $MRK's suvorexant will sell as Belsomra, but dosing issue will likely limit its market value. Article | Follow @DamianFierce

@EmilyMFierce: Science! What's Up With That: Why It's So Hard to Catch Your Own Typos. Wired story | Follow @EmilyMFierce

> InterMune buyout rumors resurface, with Roche, Sanofi on the short list. More

> Allergan bets up to $588M on Taris' bladder candidate. News

> Prefer a Swiss tax rate? Basilea chief says he's ready to parley. Story

> AstraZeneca squares off against Roche in blockbuster PhIII asthma showdown. Article

Vaccines News

> Sanofi's high-dose Fluzone beats standard-dose version in protecting seniors. More

> Researchers retract narcolepsy study linked to Glaxo's Pandemrix. Report

> Health Canada signs off on GSK's plans to improve its flu vaccine plant. More

> Pfizer's Prevnar gets $2B boost with CDC nod in older adults. Article

> Dendreon's debt plans could leave stockholders in the lurch. Story

Pharma Manufacturing News

> Shire takes over production of Buccolam after contractor fails. Article

> Amgen recalls Aranesp syringes contaminated with polyester. Report

> Indian regulator lays down new standards for its inspectors. More

> Baxter recalls another lot of saline solution as shortage persists. Story

> Canada says GSK flu vaccine plant is on track; the FDA remains mum. Item

> Wockhardt's run-ins with the FDA cost it most of its profits for a quarter. Article

And Finally... Bisphosphonate drugs for osteoporosis don't reduce the risk of breast cancer as previously thought, a study found. Report

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.